Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 casesPhilip C. Mack, David R. Gandara, Kimberly C. Banks et al.|Cancer|2020Cited by 184
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S. Andrews, Jeff Allen, Li Liu et al.|Clinical Cancer Research|2025Cited by 19
Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials.Hillary Stires, Névine Zariffa, Megan Eisele et al.|Journal of Clinical Oncology|2023Cited by 4
Supplementary Figure S5 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S. Andrews, Jeff Allen, Névine Zariffa et al.|Unknown|2025Cited by 0
Supplementary Figure S1 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S. Andrews, Jeff Allen, Névine Zariffa et al.|Unknown|2025Cited by 0